Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$19.3 million.

  • C4 Therapeutics' Net Cash Flow fell 4369.11% to -$19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$840000.0, marking a year-over-year increase of 3698.42%. This contributed to the annual value of -$71.1 million for FY2024, which is 17328.97% down from last year.
  • As of Q3 2025, C4 Therapeutics' Net Cash Flow stood at -$19.3 million, which was down 4369.11% from $26.9 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Net Cash Flow high stood at $184.9 million for Q2 2021, and its period low was -$118.4 million during Q3 2021.
  • For the 5-year period, C4 Therapeutics' Net Cash Flow averaged around -$6.4 million, with its median value being -$7.7 million (2022).
  • Over the last 5 years, C4 Therapeutics' Net Cash Flow had its largest YoY gain of 44718.76% in 2021, and its largest YoY loss of 42003.71% in 2021.
  • Quarter analysis of 5 years shows C4 Therapeutics' Net Cash Flow stood at -$84.6 million in 2021, then skyrocketed by 76.6% to -$19.8 million in 2022, then soared by 431.4% to $65.6 million in 2023, then crashed by 106.33% to -$4.1 million in 2024, then plummeted by 366.22% to -$19.3 million in 2025.
  • Its last three reported values are -$19.3 million in Q3 2025, $26.9 million for Q2 2025, and -$4.2 million during Q1 2025.